BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22749038)

  • 1. Characterization of 17.94, a novel anaplastic Wilms' tumor cell line.
    Brown KW; Charles A; Dallosso A; White G; Charlet J; Standen GR; Malik K
    Cancer Genet; 2012 Jun; 205(6):319-26. PubMed ID: 22749038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq.
    Phelps HM; Al-Jadiry MF; Corbitt NM; Pierce JM; Li B; Wei Q; Flores RR; Correa H; Uccini S; Frangoul H; Alsaadawi AR; Al-Badri SAF; Al-Darraji AF; Al-Saeed RM; Al-Hadad SA; Lovvorn Iii HN
    World J Pediatr; 2018 Dec; 14(6):585-593. PubMed ID: 30155617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study.
    Gadd S; Huff V; Huang CC; Ruteshouser EC; Dome JS; Grundy PE; Breslow N; Jennings L; Green DM; Beckwith JB; Perlman EJ
    Neoplasia; 2012 Aug; 14(8):742-56. PubMed ID: 22952427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children.
    Haruta M; Arai Y; Watanabe N; Fujiwara Y; Honda S; Ohshima J; Kasai F; Nakadate H; Horie H; Okita H; Hata J; Fukuzawa M; Kaneko Y
    Cancer Sci; 2012 Jun; 103(6):1129-35. PubMed ID: 22409817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
    Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
    Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stratification of Wilms tumor by genetic and epigenetic analysis.
    Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
    Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology, genetics and cytogenetics of Wilms' tumour.
    Md Zin R; Murch A; Charles A
    Pathology; 2011 Jun; 43(4):302-12. PubMed ID: 21516053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of Wilms' tumor from a resource-constrained region of sub-Saharan Africa.
    Murphy AJ; Axt JR; de Caestecker C; Pierce J; Correa H; Seeley EH; Caprioli RM; Newton MW; de Caestecker MP; Lovvorn HN
    Int J Cancer; 2012 Sep; 131(6):E983-94. PubMed ID: 22437966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
    Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
    Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
    Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
    Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canonical WNT signalling determines lineage specificity in Wilms tumour.
    Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
    Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
    Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
    Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
    Ruteshouser EC; Robinson SM; Huff V
    Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
    Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
    Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor.
    Dallosso AR; Hancock AL; Szemes M; Moorwood K; Chilukamarri L; Tsai HH; Sarkar A; Barasch J; Vuononvirta R; Jones C; Pritchard-Jones K; Royer-Pokora B; Lee SB; Owen C; Malik S; Feng Y; Frank M; Ward A; Brown KW; Malik K
    PLoS Genet; 2009 Nov; 5(11):e1000745. PubMed ID: 19956686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
    Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
    Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
    Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
    Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, Pathologic, and Genetic Features of Wilms Tumors With WTX Gene Mutation.
    Alexandrescu S; Akhavanfard S; Harris MH; Vargas SO
    Pediatr Dev Pathol; 2017; 20(2):105-111. PubMed ID: 28326956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
    Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.